Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IMV Inc IMVIQ

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.

Recent & Breaking News (GREY:IMVIQ)

IMV Reports Update on COVID-19 Vaccine Program

Business Wire December 28, 2020

Durable Clinical Benefits Induced by IMV's T Cell Therapy in Combination With Merck's Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

Business Wire December 6, 2020

IMV's Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer

Business Wire December 3, 2020

IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy

Business Wire November 13, 2020

IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update

Business Wire November 12, 2020

IMV Strengthens Leadership Team with Appointment of Andrew Hall as Chief Business Officer

Business Wire November 10, 2020

IMV to Participate in Two Upcoming Investor Conferences

Business Wire November 9, 2020

IMV's T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck's Keytruda® in PD-L1 Positive Patients with r/r DLBCL

Business Wire November 9, 2020

Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV's T Cell Therapy in Combination With Merck's Keytruda® in Patients With r/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting

Business Wire November 4, 2020

IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy

Business Wire October 29, 2020

IMV Inc. Re-establishes At-the-Market Facility

Business Wire October 16, 2020

Biomarkers Associated With Clinical Response in Patients With r/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented at the Upcoming SITC Annual Meeting

Business Wire October 15, 2020

IMV Provides Updates On COVID-19 Vaccine Program

Business Wire October 8, 2020

IMV CEO to Participate at the Vaccines Panel of the Sachs Associates 20th Annual Biotech in Europe Forum

Business Wire September 16, 2020

LD Micro -- 360 Companies Set to Present this Week

Accesswire August 31, 2020

IMV to Participate at Four Upcoming Investor Conferences

Business Wire August 26, 2020

IMV Inc. Announces Second Quarter 2020 Financial Results

Business Wire August 12, 2020

LD Micro - Announces Preliminary List of Presenters for the LD 500

Accesswire August 5, 2020

IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study

Business Wire August 5, 2020

IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020

Business Wire August 3, 2020